Exploiting KRAS-mediated metabolic reprogramming as a therapeutic target

Half of all colorectal cancers bear KRAS-activating mutations that affect the metabolic dependencies of cancer cells and drive resistance to commonly used drugs. A new study provides insights into KRAS-driven metabolic rewiring and identifies a new therapeutic target for KRAS-mutant cancers.

Automated summary

Half of colorectal cancers have KRAS-activating mutations, which affect cancer cells' metabolic dependencies and lead to resistance to common drugs. A new study reveals the metabolic rewiring driven by KRAS and identifies a new therapeutic target for KRAS-mutant cancers.